Toward a therapeutic window for antiplatelet therapy in the elderly

European Heart Journal

Volumn 33, Issue 10, 2012, Pages 1187-1189

  Gurbel, Paul A ^a   Ohman, E Magnus ^b   Jeong, Young Hoon ^c   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR; CLOPIDOGREL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; BLEEDING; BLEEDING TIME; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; ISCHEMIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 84861401402     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr458     Document Type: Review

References (13)

1. Mari D, Coppola R, Provenzano R. Hemostasis factors and aging. Exp Gerontol 2008;43:66-73.
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913. (Pubitemid 36736631)
3. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50: 1822-1834. (Pubitemid 350007957)
4. Silvain J, Cayla G, Hulot J-S, Finzi J, Kernieis M, O'Connor SA, Bellemain-Appaix A, Bathelemy O, Beygui F, Collet J-P, Montalescot G. High on-thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study. Eur Heart J 2012;33:1241-1249.
5. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-2585.
6. Price MJ, Berger PB, Teirstein PS et al. GRAVITAS Investigators. Standard-vs highdose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-1105.
7. Michelson AD, Frelinger AL 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD; TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753-1763.
8. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-857.
9. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-762.
10. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
11. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, Peterson ED, Philippides GJ, Theroux P, Wenger NK, Zidar JP, Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2011;57:e215-e367.
12. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M. PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
13. Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM; TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16-22.e1